NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 15.34 against a street estimate of 12.60 — a beat of 21.7%.
with an average price target of ₹2,225.62.
CONFIDENT Emcure posted 22.8% revenue growth to INR 2,580 cr, led by international (+34.2%) and domestic recovery (+10.2%). Leadership restructured; Gennova now 100% owned. Targeting low-to-mid-teen growth and 70–100 bps EBITDA margin expansion in FY27. Q1 FY27 All regions contributed to robust international growth. Europe benefited from amphotericin B ramp-up and base business. Canada showed broad-based portfolio strength. ROW driven primarily by ARV (~65% of mix in Q1, expected ~50–55% for full year) with emerging markets showing strong momentum. Analysts probed organic growth quality (6–7% ex-in-licensed vs 10.2% reported), ROW sustainability amid high prior-year base (management confident in steady ARV + non-ARV mix), and Poviztra market penetration amid 40–50 competitors (management emphasized innovator advantage and month-on-month traction). Management reassured that consolidation …
Full summary in the app.
| Document | Date |
|---|---|
| Annual report FY2026 EMCURE PHARMACEUTICALS LIMITED – ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: INR 92,035 Million, up 16.6% Y-o-Y • C | 2026-08-28 |
| Q1 FY27 earnings call EMCURE PHARMACEUTICALS LIMITED – Q1 FY27 SUMMARY --- HEADLINE NUMBERS • Revenue: INR 2,580 crore, up 22.8% year-on-year • EBITDA: INR 508 crore, up | 2026-08-12 |
| Investor presentation · Q1 FY27 EMCURE PHARMACEUTICALS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue: INR 25,804 million, up 22.8% YoY (Q1 FY26: INR 21,005 million) • EBITDA | 2026-08-06 |
| Quarterly results · Q1 FY27 EMCURE PHARMACEUTICALS LIMITED – Q1 FY2026-27 SUMMARY --- HEADLINE NUMBERS CONSOLIDATED (Quarter ended June 30, 2026) • Revenue from operations: ₹2 | 2026-08-06 |
| Investor presentation · Q4 FY26 EMCURE PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: INR 9,204 crore, up 16.6% YoY (FY25: INR 7,896 crore) • TTM Reven | 2026-06-12 |
| Q4 FY26 earnings call EMCURE PHARMACEUTICALS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • FY26 revenue: INR9,204 crores, growth of 16.6% year-on-year, crossed $1 billion | 2026-05-11 |
| Investor presentation | 2026-05-05 |
| Investor presentation · Q3 FY26 EMCURE PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • TTM Revenue (Dec 2025): INR 8,850 Cr • FY25 Revenue: INR 7,896 Cr (18%+ growth | 2026-02-20 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹3.60 / share ex-date Sep 4, 2026 | 2026-09-04 |
| Dividend | ₹3 / share ex-date Aug 14, 2025 | 2025-08-14 |
| Announcement | Date |
|---|---|
| Completion of acquisition of shares in Gennova Biopharmaceuticals Emcure Pharmaceuticals has completed its acquisition of shares in Gennova Biopharmaceuticals Limited. This strategic acquisition expands Emcure's portfolio and capabilities in the biopharmac | 2026-07-22 |
| Acquisition announced by pharmaceutical company Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition | 2026-07-13 |
| Acquisition announced by the company Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition | 2026-07-03 |
| Acquisition announced Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition | 2026-04-01 |
| Acquisition announced by pharmaceutical company Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition | 2025-10-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Emcure Pharmaceuticals Ltd — free to start.
Google PlayApp StoreData updated 2026-09-18.